D
Finch Therapeutics Group, Inc.
FNCH
$13.45
-$0.55-3.93%
D
Sell
8/15/2024Upgraded
Finch Therapeutics Group, Inc. (FNCH) was upgraded to D- from E+ on 8/15/2024 due to a noticeable increase in the volatility index and total return index.
Finch Therapeutics Group, Inc. (FNCH) was upgraded to D- from E+ on 8/15/2024 due to a noticeable increase in the volatility index and total return index.
E
Sell
6/25/2024Upgraded
Finch Therapeutics Group, Inc. (FNCH) was upgraded to E+ from E on 6/25/2024 due to an increase in the volatility index.
Finch Therapeutics Group, Inc. (FNCH) was upgraded to E+ from E on 6/25/2024 due to an increase in the volatility index.
E
Sell
6/10/2024Downgrade
Finch Therapeutics Group, Inc. (FNCH) was downgraded to E from E+ on 6/10/2024 due to a decline in the volatility index, growth index and total return index. Earnings per share declined from -$1.894 to -$2.4138, operating cash flow declined 17.7% from -$3.71M to -$4.36M, and EBIT declined 10.32% from -$4.68M to -$5.16M.
Finch Therapeutics Group, Inc. (FNCH) was downgraded to E from E+ on 6/10/2024 due to a decline in the volatility index, growth index and total return index. Earnings per share declined from -$1.894 to -$2.4138, operating cash flow declined 17.7% from -$3.71M to -$4.36M, and EBIT declined 10.32% from -$4.68M to -$5.16M.
E
Sell
5/20/2024Upgraded
Finch Therapeutics Group, Inc. (FNCH) was upgraded to E+ from E on 5/20/2024 due to an increase in the volatility index.
Finch Therapeutics Group, Inc. (FNCH) was upgraded to E+ from E on 5/20/2024 due to an increase in the volatility index.
E
Sell
5/3/2024Downgrade
Finch Therapeutics Group, Inc. (FNCH) was downgraded to E from E+ on 5/3/2024 due to a decline in the volatility index, growth index and total return index.
Finch Therapeutics Group, Inc. (FNCH) was downgraded to E from E+ on 5/3/2024 due to a decline in the volatility index, growth index and total return index.
E
Sell
4/18/2024Upgraded
Finch Therapeutics Group, Inc. (FNCH) was upgraded to E+ from E on 4/18/2024 due to an increase in the volatility index and solvency index.
Finch Therapeutics Group, Inc. (FNCH) was upgraded to E+ from E on 4/18/2024 due to an increase in the volatility index and solvency index.
E
Sell
3/28/2024Downgrade
Finch Therapeutics Group, Inc. (FNCH) was downgraded to E from E+ on 3/28/2024 due to a decline in the growth index, volatility index and solvency index. Earnings per share declined from -$1.5053 to -$1.894, and EBIT declined 25.33% from -$3.74M to -$4.68M.
Finch Therapeutics Group, Inc. (FNCH) was downgraded to E from E+ on 3/28/2024 due to a decline in the growth index, volatility index and solvency index. Earnings per share declined from -$1.5053 to -$1.894, and EBIT declined 25.33% from -$3.74M to -$4.68M.
E
Sell
3/15/2024Upgraded
Finch Therapeutics Group, Inc. (FNCH) was upgraded to E+ from E on 3/15/2024 due to an increase in the volatility index.
Finch Therapeutics Group, Inc. (FNCH) was upgraded to E+ from E on 3/15/2024 due to an increase in the volatility index.
E
Sell
2/29/2024Downgrade
Finch Therapeutics Group, Inc. (FNCH) was downgraded to E from E+ on 2/29/2024 due to a decline in the volatility index.
Finch Therapeutics Group, Inc. (FNCH) was downgraded to E from E+ on 2/29/2024 due to a decline in the volatility index.
E
Sell
2/8/2024Upgraded
Finch Therapeutics Group, Inc. (FNCH) was upgraded to E+ from E on 2/8/2024 due to an increase in the volatility index.
Finch Therapeutics Group, Inc. (FNCH) was upgraded to E+ from E on 2/8/2024 due to an increase in the volatility index.
E
Sell
1/24/2024Downgrade
Finch Therapeutics Group, Inc. (FNCH) was downgraded to E from E+ on 1/24/2024 due to a decline in the volatility index.
Finch Therapeutics Group, Inc. (FNCH) was downgraded to E from E+ on 1/24/2024 due to a decline in the volatility index.
E
Sell
1/8/2024Upgraded
Finch Therapeutics Group, Inc. (FNCH) was upgraded to E+ from E on 1/8/2024 due to an increase in the volatility index.
Finch Therapeutics Group, Inc. (FNCH) was upgraded to E+ from E on 1/8/2024 due to an increase in the volatility index.
E
Sell
12/22/2023Downgrade
Finch Therapeutics Group, Inc. (FNCH) was downgraded to E from E+ on 12/22/2023 due to a decline in the volatility index, solvency index and total return index. Debt to equity increased from 0.06 to 0.08.
Finch Therapeutics Group, Inc. (FNCH) was downgraded to E from E+ on 12/22/2023 due to a decline in the volatility index, solvency index and total return index. Debt to equity increased from 0.06 to 0.08.
E
Sell
12/14/2022Downgrade
Finch Therapeutics Group, Inc. (FNCH) was downgraded to E+ from D- on 12/14/2022 due to a decline in the volatility index.
Finch Therapeutics Group, Inc. (FNCH) was downgraded to E+ from D- on 12/14/2022 due to a decline in the volatility index.
D
Sell
11/29/2022Upgraded
Finch Therapeutics Group, Inc. (FNCH) was upgraded to D- from E+ on 11/29/2022 due to an increase in the volatility index.
Finch Therapeutics Group, Inc. (FNCH) was upgraded to D- from E+ on 11/29/2022 due to an increase in the volatility index.
E
Sell
11/14/2022Downgrade
Finch Therapeutics Group, Inc. (FNCH) was downgraded to E+ from D- on 11/14/2022 due to a substantial decline in the growth index and solvency index. Earnings per share declined from -$0.4771 to -$0.8459, total revenue declined 61.77% from $361 to $138, and operating cash flow declined 20.55% from -$15.84M to -$19.09M.
Finch Therapeutics Group, Inc. (FNCH) was downgraded to E+ from D- on 11/14/2022 due to a substantial decline in the growth index and solvency index. Earnings per share declined from -$0.4771 to -$0.8459, total revenue declined 61.77% from $361 to $138, and operating cash flow declined 20.55% from -$15.84M to -$19.09M.
D
Sell
11/10/2022Downgrade
Finch Therapeutics Group, Inc. (FNCH) was downgraded to D- from D on 11/10/2022 due to a decline in the volatility index.
Finch Therapeutics Group, Inc. (FNCH) was downgraded to D- from D on 11/10/2022 due to a decline in the volatility index.
D
Sell
8/15/2022Upgraded
Finch Therapeutics Group, Inc. (FNCH) was upgraded to D from D- on 8/15/2022 due to a noticeable increase in the growth index. Operating cash flow increased 38.24% from -$25.65M to -$15.84M, EBIT increased 11.61% from -$24.58M to -$21.73M, and earnings per share increased from -$0.5169 to -$0.4771.
Finch Therapeutics Group, Inc. (FNCH) was upgraded to D from D- on 8/15/2022 due to a noticeable increase in the growth index. Operating cash flow increased 38.24% from -$25.65M to -$15.84M, EBIT increased 11.61% from -$24.58M to -$21.73M, and earnings per share increased from -$0.5169 to -$0.4771.
D
Sell
5/17/2022Upgraded
Finch Therapeutics Group, Inc. (FNCH) was upgraded to D- from E+ on 5/17/2022 due to an increase in the growth index.
Finch Therapeutics Group, Inc. (FNCH) was upgraded to D- from E+ on 5/17/2022 due to an increase in the growth index.
E
Sell
5/13/2022Downgrade
Finch Therapeutics Group, Inc. (FNCH) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index and total return index.
Finch Therapeutics Group, Inc. (FNCH) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index and total return index.
D
Sell
5/4/2022Upgraded
Finch Therapeutics Group, Inc. (FNCH) was upgraded to D from E+ on 05/04/2022.
Finch Therapeutics Group, Inc. (FNCH) was upgraded to D from E+ on 05/04/2022.
E
Sell
5/1/2022Downgrade
Finch Therapeutics Group, Inc. (FNCH) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index and total return index.
Finch Therapeutics Group, Inc. (FNCH) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index and total return index.
D
Sell
4/22/2022Upgraded
Finch Therapeutics Group, Inc. (FNCH) was upgraded to D from E+ on 4/22/2022 due to an increase in the volatility index and valuation index.
Finch Therapeutics Group, Inc. (FNCH) was upgraded to D from E+ on 4/22/2022 due to an increase in the volatility index and valuation index.
E
Sell
4/20/2022Downgrade
Finch Therapeutics Group, Inc. (FNCH) was downgraded to E+ from D- on 4/20/2022 due to a decline in the volatility index and total return index.
Finch Therapeutics Group, Inc. (FNCH) was downgraded to E+ from D- on 4/20/2022 due to a decline in the volatility index and total return index.
D
Sell
4/18/2022Downgrade
Finch Therapeutics Group, Inc. (FNCH) was downgraded to D- from D on 4/18/2022 due to a major decline in the efficiency index, growth index and total return index. Total revenue declined 92.89% from $11.34M to $806, EBIT declined 91.91% from -$9.93M to -$19.06M, and net income declined 91.41% from -$9.96M to -$19.06M.
Finch Therapeutics Group, Inc. (FNCH) was downgraded to D- from D on 4/18/2022 due to a major decline in the efficiency index, growth index and total return index. Total revenue declined 92.89% from $11.34M to $806, EBIT declined 91.91% from -$9.93M to -$19.06M, and net income declined 91.41% from -$9.96M to -$19.06M.
D
Sell
4/1/2022Upgraded
Finch Therapeutics Group, Inc. (FNCH) was upgraded to D from D- on 4/1/2022 due to an increase in the valuation index.
Finch Therapeutics Group, Inc. (FNCH) was upgraded to D from D- on 4/1/2022 due to an increase in the valuation index.
D
Sell
12/1/2021Upgraded
Finch Therapeutics Group, Inc. (FNCH) was upgraded to D- from E+ on 12/1/2021 due to an increase in the total return index.
Finch Therapeutics Group, Inc. (FNCH) was upgraded to D- from E+ on 12/1/2021 due to an increase in the total return index.
E
Sell
11/26/2021Upgraded
Finch Therapeutics Group, Inc. (FNCH) was upgraded to E+ from E on 11/26/2021 due to a large increase in the growth index, volatility index and solvency index. Total revenue increased 300.81% from $2.83M to $11.34M, EBIT increased 41.63% from -$17.02M to -$9.93M, and operating cash flow increased 39.66% from -$23.78M to -$14.35M.
Finch Therapeutics Group, Inc. (FNCH) was upgraded to E+ from E on 11/26/2021 due to a large increase in the growth index, volatility index and solvency index. Total revenue increased 300.81% from $2.83M to $11.34M, EBIT increased 41.63% from -$17.02M to -$9.93M, and operating cash flow increased 39.66% from -$23.78M to -$14.35M.
E
Sell
9/1/2021Upgraded
Finch Therapeutics Group, Inc. (FNCH) was upgraded to E from E- on 9/1/2021 due to an increase in the volatility index and total return index.
Finch Therapeutics Group, Inc. (FNCH) was upgraded to E from E- on 9/1/2021 due to an increase in the volatility index and total return index.
E
Sell
8/12/2021None
Finch Therapeutics Group, Inc. (FNCH) was downgraded to E- from U on 08/12/2021.
Finch Therapeutics Group, Inc. (FNCH) was downgraded to E- from U on 08/12/2021.
OTC PK
03/13/2025 3:45PM Eastern
Quotes delayed
